The Central Drugs Standard Control Organization (CDSCO) has approved a landmark therapy combination for Indian patients. Astellas Pharma India announced that PADCEV (enfortumab vedotin) combined with pembrolizumab is now available. Specifically, this regimen is for adult patients with unresectable or metastatic urothelial cancer eligible for platinum chemotherapy. This approval marks India's first combination therapy offering an alternative to standard platinum-based chemotherapy for advanced urothelial cancer. Therefore, clinicians now have a highly effective first-line therapeutic option.

Clinical Efficacy of the New Regimen in Advanced Urothelial Cancer

This approval relies on robust clinical evidence. Specifically, the Phase 3 EV-302 clinical trial evaluated the efficacy and safety of this combination. The study compared the drug combination directly against standard platinum-based chemotherapy. Remarkably, the immunotherapy combination nearly doubled the median overall survival of patients. Patients receiving the new combination achieved a median overall survival of 31.5 months. In contrast, those on standard chemotherapy experienced a median overall survival of only 16.1 months. Consequently, this represents a massive 53% reduction in the risk of death. Furthermore, the combination significantly extended progression-free survival. The median progression-free survival reached 12.5 months compared to 6.3 months with traditional chemotherapy. Therefore, this trial demonstrates unprecedented survival benefits for advanced urothelial cancer.

Safety Profile and Tolerability

Safety remains a critical factor during oncology treatments. Overall, the safety results of the EV-302 trial aligned with previous studies. Clinicians observed no new safety signals during the clinical evaluation. However, patients did experience some treatment-related side effects. The most common grade 3 or higher adverse events included maculo-papular rash and hyperglycemia. Additionally, patients experienced neutropenia, peripheral sensory neuropathy, diarrhea, and anemia. Therefore, oncologists must carefully monitor patients during therapy. Because the regimen improves survival, proactive side effect management is highly rewarding. Consequently, supportive care plays a vital role in optimizing these clinical outcomes.

Frequently Asked Questions

Q1: What is the newly approved combination therapy for urothelial cancer in India?

The CDSCO has approved enfortumab vedotin in combination with pembrolizumab as a first-line treatment option for adult patients with advanced urothelial cancer.

Q2: How does the new combination compare to standard chemotherapy?

In clinical trials, this combination nearly doubled overall survival to 31.5 months, compared to 16.1 months for traditional chemotherapy, reducing the risk of death by 53%.

Q3: What are the most common side effects of this treatment?

Common grade 3 or higher side effects include maculo-papular rash, hyperglycemia, neutropenia, peripheral neuropathy, diarrhea, and anemia. Therefore, oncologists must monitor patients carefully.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. PADCEVTM (enfortumab vedotin) in Combination with pembrolizumab is Now Availablefor the first-line treatment of adult patients with unresectable or metastaticurothelial cancer who are eligible for platinum-containing chemotherapy in India - ETHealthworld


2. Powles T, Valderrama BP, Gupta S, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. New England Journal of Medicine. 2024;390(10):875-888.